Last mentioned: Mar 6, 2026
PROF Break-even
Target window for Profound Medical to reach cash-flow neutrality.
Kura NDA Submission
Anticipated filing for ziftomenib with the FDA.
Earnings Release
Companies report Q4 and Full Year 2025 results, signaling a shift to 2026 commercial targets.
Q4 Earnings Release
Both companies report pivotal year-end results.
Fiscal Year End
Med-tech firms report record system utilization rates for the 2025 calendar year.
Clinical Enrollment
Atea Pharmaceuticals completes enrollment for the Phase 2 Hepatitis C (HCV) trial.
Reimbursement Milestone
Profound Medical receives expanded CPT code coverage for TULSA-PRO in the U.S.
CPT Code Activation
Category 1 CPT codes for TULSA-PRO go live in the U.S.
Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a pivotal shift toward commercial execution. Kura is nearing an NDA submission for its lead leukemia candidate, while Profound saw record revenue growth following the first full year of Category 1 CPT code implementation.
Kura Oncology and Profound Medical reported fourth-quarter 2025 results, highlighting a pivotal shift toward commercial execution in precision oncology and medical technology. While both companies faced revenue headwinds, Kura's launch of KOMZIFTI and Profound's surprise earnings beat signal a maturing landscape for specialized therapies.
Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a critical transition period as they navigate commercial launches and reimbursement hurdles. While both firms faced revenue headwinds, Kura's $7 billion AML opportunity and Profound's significant EPS beat underscore a shifting landscape in oncology and incision-less surgery.
Rumble and OptimizeRx reported their fourth-quarter and full-year 2025 financial results, highlighting significant growth in cloud infrastructure and digital health engagement. These results underscore a broader trend of resilient demand for specialized SaaS platforms and independent cloud ecosystems.
Rumble and a cohort of mid-cap growth companies reported 2025 year-end results, highlighting a shift from pure-play growth to infrastructure-led sustainability. These reports underscore a broader trend of 'platformization' across the technology and biotech sectors as companies seek to insulate themselves from volatile market conditions.
A cluster of mid-cap and small-cap companies, led by Rumble and Atea Pharmaceuticals, released fourth-quarter and full-year 2025 results, signaling a period of strategic transition. The reports highlight a divergence between high-growth digital infrastructure and the clinical-stage healthcare sector as firms navigate the post-2024 economic landscape.
Atea Pharmaceuticals and Profound Medical headlined a busy earnings day for the biotech sector, revealing critical updates on antiviral pipelines and therapeutic device adoption. As companies report full-year 2025 results, the focus remains on cash preservation and the transition from R&D to commercial execution.
Atea Pharmaceuticals and Profound Medical headlined a series of Q4 2025 earnings reports, highlighting a shift toward commercial scaling in medical devices and late-stage clinical milestones in biotech. These results underscore a sector-wide focus on capital preservation and high-margin recurring revenue models.